Global Blood Therapeutics Financial Statements (GBT)
|
|
Report date
|
|
|
27.02.2018 |
27.02.2019 |
26.02.2020 |
24.02.2021 |
23.02.2022 |
|
08.08.2022 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
2.11 |
123.8 |
194.7 |
|
234.9 |
Operating Income, bln rub |
|
|
-119.2 |
-182.7 |
-281.3 |
-243.2 |
-287.1 |
|
-297.4 |
EBITDA, bln rub |
? |
|
-115.4 |
-169.6 |
-256.8 |
-226.9 |
-278.5 |
|
-288.4 |
Net profit, bln rub |
? |
|
-117.0 |
-174.2 |
-266.8 |
-247.6 |
-303.1 |
|
-326.4 |
|
OCF, bln rub |
? |
|
-93.0 |
-135.4 |
-194.4 |
-211.9 |
-256.8 |
|
-249.4 |
CAPEX, bln rub |
? |
|
3.10 |
4.82 |
3.46 |
8.75 |
3.23 |
|
1.95 |
FCF, bln rub |
? |
|
-96.1 |
-140.2 |
-197.9 |
-220.6 |
-260.0 |
|
-251.3 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
OPEX, bln rub |
|
|
119.2 |
182.7 |
291.6 |
366.0 |
479.1 |
|
529.7 |
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.048 |
1.99 |
3.32 |
|
4.45 |
R&D, bln rub |
|
|
87.8 |
131.3 |
174.6 |
155.1 |
212.1 |
|
227.1 |
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
9.81 |
15.5 |
|
24.7 |
|
Assets, bln rub |
|
|
356.7 |
617.6 |
796.1 |
724.0 |
939.2 |
|
870.4 |
Net Assets, bln rub |
? |
|
318.8 |
572.8 |
578.7 |
416.2 |
196.4 |
|
118.4 |
Debt, bln rub |
|
|
0.000 |
0.000 |
75.4 |
153.7 |
659.6 |
|
658.4 |
Cash, bln rub |
|
|
314.8 |
477.5 |
610.0 |
560.9 |
684.7 |
|
517.2 |
Net debt, bln rub |
|
|
-314.8 |
-477.5 |
-534.5 |
-407.2 |
-25.1 |
|
141.2 |
|
Ordinary share price, rub |
|
|
39.4 |
41.1 |
79.5 |
43.3 |
29.3 |
|
67.5 |
Number of ordinary shares, mln |
|
|
42.3 |
51.2 |
58.3 |
61.3 |
62.9 |
|
65.6 |
|
Market cap, bln rub |
|
|
1 665 |
2 100 |
4 636 |
2 656 |
1 842 |
|
4 428 |
EV, bln rub |
? |
|
1 351 |
1 622 |
4 101 |
2 249 |
1 817 |
|
4 569 |
Book value, bln rub |
|
|
319 |
573 |
579 |
416 |
196 |
|
118 |
|
EPS, rub |
? |
|
-2.76 |
-3.41 |
-4.57 |
-4.04 |
-4.82 |
|
-4.98 |
FCF/share, rub |
|
|
-2.27 |
-2.74 |
-3.39 |
-3.60 |
-4.13 |
|
-3.83 |
BV/share, rub |
|
|
7.53 |
11.2 |
9.92 |
6.79 |
3.12 |
|
1.80 |
|
EBITDA margin, % |
? |
|
|
|
-12 184% |
-183.3% |
-143.0% |
|
-122.8% |
Net margin, % |
? |
|
|
|
-12 655% |
-200.0% |
-155.6% |
|
-139.0% |
FCF yield, % |
? |
|
-5.77% |
-6.68% |
-4.27% |
-8.31% |
-14.1% |
|
-5.68% |
ROE, % |
? |
|
-36.7% |
-30.4% |
-46.1% |
-59.5% |
-154.3% |
|
-275.7% |
ROA, % |
? |
|
-32.8% |
-28.2% |
-33.5% |
-34.2% |
-32.3% |
|
-37.5% |
|
P/E |
? |
|
-14.2 |
-12.1 |
-17.4 |
-10.7 |
-6.08 |
|
-13.6 |
P/FCF |
|
|
-17.3 |
-15.0 |
-23.4 |
-12.0 |
-7.08 |
|
-17.6 |
P/S |
? |
|
|
|
2 199 |
21.5 |
9.46 |
|
18.9 |
P/BV |
? |
|
5.22 |
3.67 |
8.01 |
6.38 |
9.38 |
|
37.4 |
EV/EBITDA |
? |
|
-11.7 |
-9.57 |
-16.0 |
-9.91 |
-6.52 |
|
-15.8 |
Debt/EBITDA |
|
|
2.73 |
2.82 |
2.08 |
1.79 |
0.09 |
|
-0.49 |
|
R&D/CAPEX, % |
|
|
2 832% |
2 722% |
5 045% |
1 772% |
6 562% |
|
11 652% |
|
CAPEX/Revenue, % |
|
|
|
|
164.1% |
7.07% |
1.66% |
|
0.83% |
|
Global Blood Therapeutics shareholders |